Across 22 studies — 16 preclinical and 6 randomized clinical trials — resveratrol consistently reduced alveolar bone loss in animal models by a striking 7.09% to 60.60%, while also lowering inflammatory cytokines and oxidative stress markers. In the six human trials, outcomes were positive but variable: probing pocket depth, bleeding index, and plaque index all improved, with reductions in local and systemic inflammatory markers. Critically, no clinical study measured radiographic bone loss — the gold-standard endpoint for periodontal progression.
The preclinical signal here is genuinely compelling. Resveratrol's dual mechanism — suppressing NF-κB-driven cytokine cascades while activating SIRT1-mediated antioxidant pathways — maps well onto the pathophysiology of periodontitis, where chronic oxidative stress and dysregulated inflammation drive irreversible bone destruction. The connection to systemic disease is also worth noting: periodontitis is independently associated with cardiovascular disease, diabetes, and cognitive decline, so an adjunctive agent addressing shared inflammatory pathways carries broader longevity implications.
However, the translational leap from rodent ligature models to human chronic periodontitis remains large. The six clinical trials suffered from small enrollment, heterogeneous delivery methods (topical gel vs. systemic supplementation), and short follow-up — making dosage optimization impossible to determine. This review is confirmatory for the animal literature and hypothesis-generating for humans, not practice-changing. Adults managing periodontal disease should regard resveratrol as a promising but unproven adjunct pending adequately powered trials.
